- Home
- RCUS vs PFLT Comparison
RCUS vs PFLT Comparison
Compare RCUS & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- PFLT
- Stock Information
- Founded
- RCUS 2015
- PFLT 2010
- Country
- RCUS United States
- PFLT United States
- Employees
- RCUS N/A
- PFLT N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- PFLT Finance: Consumer Services
- Sector
- RCUS Health Care
- PFLT Finance
- Exchange
- RCUS Nasdaq
- PFLT Nasdaq
- Market Cap
- RCUS 727.1M
- PFLT 808.2M
- IPO Year
- RCUS 2018
- PFLT N/A
- Fundamental
- Price
- RCUS $8.28
- PFLT $10.08
- Analyst Decision
- RCUS Buy
- PFLT Buy
- Analyst Count
- RCUS 11
- PFLT 4
- Target Price
- RCUS $25.33
- PFLT $11.38
- AVG Volume (30 Days)
- RCUS 1.2M
- PFLT 912.4K
- Earning Date
- RCUS 05-06-2025
- PFLT 05-12-2025
- Dividend Yield
- RCUS N/A
- PFLT 12.20%
- EPS Growth
- RCUS N/A
- PFLT 16.92
- EPS
- RCUS N/A
- PFLT 1.37
- Revenue
- RCUS $141,000,000.00
- PFLT $215,391,000.00
- Revenue This Year
- RCUS N/A
- PFLT $48.14
- Revenue Next Year
- RCUS $25.77
- PFLT $9.03
- P/E Ratio
- RCUS N/A
- PFLT $7.37
- Revenue Growth
- RCUS N/A
- PFLT 47.56
- 52 Week Low
- RCUS $6.50
- PFLT $8.82
- 52 Week High
- RCUS $18.98
- PFLT $12.02
- Technical
- Relative Strength Index (RSI)
- RCUS 48.63
- PFLT 48.36
- Support Level
- RCUS $7.06
- PFLT $9.98
- Resistance Level
- RCUS $9.35
- PFLT $10.18
- Average True Range (ATR)
- RCUS 0.55
- PFLT 0.17
- MACD
- RCUS 0.06
- PFLT 0.06
- Stochastic Oscillator
- RCUS 53.28
- PFLT 79.49
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.